Overcoming the Donor Selection Challenges to Drive Success in Cell and Gene Therapy Development and Commercialization
August 3, 2023The promise for cell and gene therapies (CGTs) to revolutionize cancer therapy is immense, yet unlocking their full potential to treat more diseases and improve patient access will depend on […]
Reframing the Inherent Donor Supply Chain Ecosystem to Support the Imminent CGT Manufacturing Boom: Recap of the Allogeneic Cell Therapies Summit 2023
June 20, 2023The field of cell and gene therapy (CGT) is undergoing a significant transformation, with a notable shift towards allogeneic platforms. Placing a spotlight on what has been deemed the ‘future […]
Creating a Robust Donor Ecosystem to Accelerate Patient Access to Cell and Gene Therapies
April 26, 2023The possibility of allogeneic “off-the-shelf” engineered T cell therapies as an alternative to overcome the limitations of autologous therapies has long been a goal for the industry, with some of […]
The Crucial Role of HLA Typing in Donor Selection for Cell and Gene Therapies
March 28, 2023The Human Leukocyte Antigens (HLA) are surface proteins on our cells and tissues serving as a mechanism for the body to distinguish between self and non-self, so our immune system […]
FAQ Blog Series: What’s the Difference between Positive and Negative Immunomagnetic Cell Separation?
March 14, 2023The simplicity and speed of immunomagnetic cell separation has made it the go-to method for isolating target cell populations since it was pioneered in 1990 by Miltenyi Biotec. The ability […]
AllCells Celebrates Women’s History Month
March 10, 2023Women’s History Month is celebrated every year in March to recognize and honor the contributions and achievements of women throughout history. The 2023 National Women’s History theme is “Celebrating Women […]
The World’s Largest Apheresis Network Serves as a Catalyst to Advance Cell and Gene Therapies
February 27, 2023Is The Industry Prepared for Another Year of Rapid Growth? The cell and gene therapy (CGT) industry is expected to grow rapidly for the next 10 years with an increasing […]
Navigating the complex world of regulations: How AllCells is changing cell therapy and protecting against product-ending events
February 23, 2023The cell therapy market is valued at 15 billion dollars and is set to double in value by 2030. Cell therapy has been instrumental in the development of treatments like […]
Better Together: Discovery Life Sciences and AllCells Join Forces
January 30, 2023In July of 2022, AllCells was acquired by Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists™. By combining over 30 years of cell and gene therapy (CGT) expertise, our […]
How AllCells’ Expanded Donor Collection Facilities Help You to Recruit the Right Donors and Scale Your Cell and Gene Therapy Development
November 7, 2022Unlike classical therapeutics (i.e., monoclonal antibodies), the raw starting materials for cell and gene therapies (CGTs) are derived from patient or donor cells. As such, these sources are not mass-produced […]
